KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) EBITDA Margin (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed EBITDA Margin for 11 consecutive years, with 10891.49% as the latest value for Q3 2024.

  • On a quarterly basis, EBITDA Margin rose 1116874.0% to 10891.49% in Q3 2024 year-over-year; TTM through Dec 2024 was 259683.33%, a 25952570.0% decrease, with the full-year FY2024 number at 4053.72%, up 361666.0% from a year prior.
  • EBITDA Margin was 10891.49% for Q3 2024 at Palvella Therapeutics, up from 72766.67% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 10891.49% in Q3 2024 to a low of 72766.67% in Q2 2024.
  • A 5-year average of 3721.27% and a median of 144.58% in 2022 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 1116874bps in 2024; the steepest drop was -7278782bps in 2024.
  • Palvella Therapeutics' EBITDA Margin stood at 916.53% in 2020, then skyrocketed by 91bps to 84.14% in 2021, then crashed by -72bps to 144.58% in 2022, then grew by 30bps to 101.46% in 2023, then surged by 10835bps to 10891.49% in 2024.
  • Per Business Quant, the three most recent readings for PVLA's EBITDA Margin are 10891.49% (Q3 2024), 72766.67% (Q2 2024), and 5808.51% (Q1 2024).